Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds

Table 1

Patients groups characteristics and volume of care data.

	SOC	NXB
Number of patients	10	10
Patients (male)	6	6
Average age (range)	49 (19–64)	48 (18–69)
Etiology	6 scalds; 3 flame; 1 contact burn∖flame	5 scalds; 5 flame
Average % TBSA burns (range)	17 (14–21)	17 (15–22)
Average stay (days) (ICU + SICU) (range)	37 (29–42)	31 (26–38)
Average ICU stay (days) (range)	8 (5–12)	6 (4–9)
95% CI volume of care	6.1–9.2	5.1–7.5
Average SICU stay (days) (range)	29 (24–34)	25 (21–29)
95% CI volume of care	26.7–30.9	23.2–26.6
Escharectomy (unit × number of patients)	1 × 7 patients	0
	2 × 3 patients
95% CI volume of care	0.95–1.64	0-0
Autograft (unit × number of patients)	1 × 10 patients	1 × 6 patients
95% CI volume of care	1-1	0.23–0.96
Blood Transfusion (unit × number of patients)	1 × 6 patients	1 × 5 patients
	2 × 2 patients
	3 × 1 patients
95% CI volume of care	0.7–1.9	0.12–0.9
NXB units consumed per patient		4 patients 6 NXB unit
		4 patients 7 NXB unit
		1 patients 8 NXB unit
		1 patients 9 NXB unit

NXB: Nexobrid; SOC: standard of care; ICU: intensive care unit; SICU: subintensive care unit; TBSA: total body surface area; CI: confidence interval.